News >

Expert Discusses Pathology for Ovarian and Endometrial Cancer

Danielle Bucco
Published: Thursday, Jul 20, 2017

Douglas A. Levine, MD

Douglas A. Levine, MD
As time goes on, there will be an interaction between molecular pathology and clinical pathology where genetic testing can lead to a more accurate pathologic diagnosis, according to Douglas A. Levine, MD.


Onclive: Can you give an overview of your presentation from the Congress of Oncology Pathology meeting?

Levine: We're talking about the interaction between oncologists and pathologists. Additionally, I talked about homologous recombination DNA repair defects in ovarian cancer, how that leads to PARP inhibition therapy, and the various recently approved FDA indications for PARP treatment. I also talk about microsatellite instability in endometrial cancer and how that has led to recent FDA approval of checkpoint blockade immune-oncology treatments. 

Can you discuss how pathology, tissue sampling, and repeat biopsies factor into ovarian and endometrial cancers?

Pathologists and oncologists work closely together to treat cancer patients. In ovarian and endometrial cancer, the tumor can evolve over time, mostly due to prior treatments. This is particularly the case with ovarian cancer based on what chemotherapy agents have been given. One of the important factors regarding tumor evolution is if the tumor has BRCA germline or somatic mutations since secondary mutations can develop over the course of treatment. Those secondary mutations can make a treatment-sensitive tumor become treatment-resistant. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication